Renal microcirculatory effects of lovastatin in a rat model of reduced renal mass

Urology

Volumn 50, Issue 5, 1997, Pages 812-817

  Glazer, Abraham A ^b   Inman, Sharon R ^b   Stowe, Nicholas T ^b   Novick, Andrew C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; LIPID; MEVINOLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYDRONEPHROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUMOR; LIPID BLOOD LEVEL; MICROCIRCULATION; NEPHRECTOMY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ANIMALS; HYDRONEPHROSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; LOVASTATIN; MICROCIRCULATION; RATS;

EID: 0030697896     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00338-5     Document Type: Article

References (28)

1. Novick AC, Gephardt G, Guz B, Steinmuller D, and Tubbs RR: Long-term follow-up after partial removal of a solitary kidney. N Engl J Med 325: 1058-1062, 1991.
2. Schimamura T, and Morrison AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79: 95-106, 1975.
3. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, and Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 245: F85-F93, 1981.
4. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 249 (3 Pt 2): F324-F337, 1985.
5. Bank N, and Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43: 1306-1312, 1993.
6. Remuzzi G, and Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384-394, 1990.
7. Diamond JR, and Karnovsky MJ: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917-924, 1988.
8. Kasiske BL, O'Donnell MP, Garvis WJ, and Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367-374, 1988.
9. Lee SK, Jin SY, Han DC, Hwang SD, and Lee HB: Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 8: 1338-1343, 1993.
10. Hafez KS, Inman SR, Stowe NT, and Novick AC: Renal hemodynamic effects of lovastatin in a renal ablation model. Urology 48: 862-867, 1996.
11. Steinhausen M, Snoei H, Parekh N, Baker R, and Johnson PC: Hydronephrosis: a new method to visualize vas afferens, efferens, and glomerular network. Kidney Int 23: 794-806, 1983.
12. Inman SR, Stowe NT, Nally JV Jr, Brouhard BH, and Vidt DG: Dietary protein does not alter intrinsic reactivity of renal microcirculation to angiotensin II in rodents. Am J Physiol 268 (2 Pt 2): F302-F308, 1995.
13. Sokal RR, and Rohlf FJ: Biometry, 2nd ed. New York, Freeman, 1981.
14. D'Amico G, and Gentile MG: Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney Int 39: S65-S69, 1991.
15. O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, and Keane WF: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22: 83-89, 1993.
16. Kasiske BL, O'Donnell MP, Cleary MP, and Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33: 667-672, 1988.
17. Harris KPG, Purkerson ML, Yates J, and Klahr S: Lovastatin ameliorates the development of glomerusclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 15: 16-23, 1990.
18. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, and Keane WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20: 651-658, 1992.
19. Modi KS, Schreiner GF, Purkerson ML, and Klahr S: Effects of probucol in renal function and structure in rats with subtotal kidney ablation. J Lab Clin Med 120: 310-317, 1992.
20. Washio M, Nanishi F, Onoyama K, Okuda S, and Fujishima M: Effects of antihyperlipidemic agent of dietary protein restriction on progressive renal deterioration in adriamycin-induced nephropathy in rats. Int Urol Nephrol 25: 295-303, 1993.
21. Brouhard BH, Takamori H, Satoh S, Inman S, Cressman M, Irwin K, Berkley V, and Stowe N: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 8: 436-440, 1994.
22. Stowe NT, Inman SR, Brouhard BH, Cressman MD, Nally JV, Vidt DG, Sato S, and Satodate R: Combined lovastatin and enalapril prevent deterioration of renal function in diabetes. J Am Soc Nephrol 4: 804, 1993.
23. Roullet JB, Xue H, Roullet CM, Fletcher WS, Cipolla MJ, Harker CT, and McCarron DA: Mevalonate availability affects human and rat resistance vessel function. J Clin Invest 96: 239-244, 1995.
24. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, and Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487, 1995.
25. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, and Ganz P: The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493, 1995.
26. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, and Novick AC: Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 156: 249-252, 1996.
27. Navar LG, Gilmore JP, Joyner WL, Steinhausen M, Edwards RM, Casellas D, Carmines PK, Zimmerhackl LB, and Yokota SD: Direct assessment of renal microcirculatory dynamics. Fed Proc 45: 2851-2861, 1986.
28. Fretschner M, Endlich E, Gulbins E, Lang RE, Schlottman K, and Steinhausen M: Effects of endothelin on the renal microcirculation of the split hydronephrotic rat kidney. Renal Physiol Biochem 14: 112-127, 1991.